3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Common Variable Immunodeficiency
1
Agammaglobulinemia
1
Interventions
venetoclax
30
Rituximab
24
ibrutinib
22
Cyclophosphamide
22
acalabrutinib
21
Specimen Handling
20
obinutuzumab
17
Biopsy
15
fludarabine
13
zanubrutinib
11
pirtobrutinib
10
fludarabine phosphate
10
Magnetic Resonance Spectroscopy
9
Bendamustine Hydrochloride
9
Lenalidomide
7
idelalisib
6
Whole-Body Irradiation
6
Mycophenolic Acid
6
CT-P10
6
ARQ531
6
Cyclosporine
5
Vincristine
4
Sirolimus
4
Prednisone
4
Peripheral Blood Stem Cell Transplantation
4
Doxorubicin
4
Blood Component Removal
4
pembrolizumab
3
Tacrolimus
3
Stem Cell Transplantation
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Lymphocytic, Chronic, B-Cell
×
Hizentra
×
90 days
×
Clear all
NCT07582432
2026-05-12
SIGMA
Grifols Biologicals, LLC
Phase 3
Recruiting
49 enrolled